Specifically, fasting glucose was reduced from 118 ± 3.4 to 108 ± 3.8 mg/dL (P = 0.039), insulin levels from 20.8 ± 3.0 to 9.3 ± 2.5 μIU/mL (P = 0.006), C-peptide levels decreased from 5.3 ± 0.6 to 3.0 ± 0.9 ng/mL (P = 0.002), and homeostasis model assessment–insulin resistance (HOMA-IR) improved from 6.0 ± 0.9 to 2.4 ± 0.8 (P = 0.001) significantly. The gene discussed is INS; the disease is Insulin resistance.